Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

An approach to suppress t… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer

Artikel i vetenskaplig tidskrift
Författare Y. H. Xue
L. Martelotto
T. Baslan
A. Vides
M. Solomon
T. T. Mai
N. Chaudhary
G. J. Riely
B. T. Li
K. Scott
F. Cechhi
Ulrika Stierner
K. Chadalavada
E. de Stanchina
S. Schwartz
T. Hembrough
G. Nanjangud
Jonas A Nilsson
S. W. Lowe
J. Reis
N. Rosen
P. Lito
Publicerad i Nat Med
Volym 23
Nummer/häfte 8
Sidor 929-+
ISSN 1078-8956
Publiceringsår 2017
Publicerad vid Sahlgrenska Cancer Center
Sidor 929-+
Språk en
Länkar dx.doi.org/10.1038/nm.4369
Ämnesord cell lung-cancer, braf-mutant, mek inhibition, raf inhibitors, phase-2, trial, open-label, melanoma, feedback, multicenter, vemurafenib, Biochemistry & Molecular Biology, Cell Biology, Research & Experimental, Medicine
Ämneskategorier Cancer och onkologi

Sammanfattning

The principles that govern the evolution of tumors exposed to targeted therapy are poorly understood. Here we modeled the selection and propagation of an amplification in the BRAF oncogene (BRAF(amp)) in patient-derived tumor xenografts (PDXs) that were treated with a direct inhibitor of the kinase ERK, either alone or in combination with other ERK signaling inhibitors. Single-cell sequencing and multiplex fluorescence in situ hybridization analyses mapped the emergence of extra-chromosomal amplification in parallel evolutionary trajectories that arose in the same tumor shortly after treatment. The evolutionary selection of BRAF(amp) was determined by the fitness threshold, the barrier that subclonal populations need to overcome to regain fitness in the presence of therapy. This differed for inhibitors of ERK signaling, suggesting that sequential monotherapy is ineffective and selects for a progressively higher BRAF copy number. Concurrent targeting of the RAF, MEK and ERK kinases, however, imposed a sufficiently high fitness threshold to prevent the propagation of subclones with high-level BRAF(amp). When administered on an intermittent schedule, this treatment inhibited tumor growth in 11/11 PDXs of lung cancer or melanoma without apparent toxicity in mice. Thus, gene amplification can be acquired and expanded through parallel evolution, enabling tumors to adapt while maintaining their intratumoral heterogeneity. Treatments that impose the highest fitness threshold will likely prevent the evolution of resistance-causing alterations and, thus, merit testing in patients.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?